<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:chebi fb="40" ids="18243">dopamine</z:chebi> transporter (DAT) is a crucial regulator of dopaminergic neurotransmission, controlling the length and brevity of dopaminergic signaling </plain></SENT>
<SENT sid="1" pm="."><plain>DAT is also the primary target of psychostimulant drugs such as cocaine and <z:chebi fb="110" ids="2679">amphetamines</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>Conversely, <z:chebi fb="0" ids="6887">methylphenidate</z:chebi> and <z:chebi fb="110" ids="2679">amphetamine</z:chebi> are both used clinically in the treatment of <z:hpo ids='HP_0007018'>attention-deficit hyperactivity disorder</z:hpo> and <z:mp ids='MP_0005279'>narcolepsy</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>The action of <z:chebi fb="110" ids="2679">amphetamines</z:chebi>, which induce transport reversal, relies primarily on the ionic composition of the intra- and extracellular milieus </plain></SENT>
<SENT sid="4" pm="."><plain>Recent findings suggest that DAT interacting proteins may also play a significant role in the modulation of reverse <z:chebi fb="40" ids="18243">dopamine</z:chebi> transport </plain></SENT>
<SENT sid="5" pm="."><plain>The pharmacological inhibition of the serine/threonine kinase αCaMKII attenuates <z:chebi fb="110" ids="2679">amphetamine</z:chebi>-triggered DAT-mediated 1-<z:chebi fb="36" ids="29309">methyl</z:chebi>-4-phenylpyridinium (<z:chebi fb="26" ids="34761">MPP</z:chebi>(+)) efflux </plain></SENT>
<SENT sid="6" pm="."><plain>More importantly, αCaMKII has also been shown to bind DAT in vitro and is therefore believed to be an important player within the DAT interactome </plain></SENT>
<SENT sid="7" pm="."><plain>Herein, we show that αCaMKII co-immunoprecipitates with DAT in mouse striatal synaptosomes </plain></SENT>
<SENT sid="8" pm="."><plain>Mice, which lack αCaMKII or which express a permanently self-inhibited αCaMKII (αCaMKII(T305D)), exhibit significantly reduced <z:chebi fb="110" ids="2679">amphetamine</z:chebi>-triggered DAT-mediated <z:chebi fb="26" ids="34761">MPP</z:chebi>(+) efflux </plain></SENT>
<SENT sid="9" pm="."><plain>Additionally, we investigated mice that mimic a neurogenetic disease known as <z:e sem="disease" ids="C0162635" disease_type="Disease or Syndrome" abbrv="">Angelman syndrome</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>These mice possess reduced αCaMKII activity </plain></SENT>
<SENT sid="11" pm="."><plain><z:e sem="disease" ids="C0162635" disease_type="Disease or Syndrome" abbrv="">Angelman syndrome</z:e> mice demonstrated an impaired DAT efflux function, which was comparable with that of the αCaMKII mutant mice, indicating that DAT-mediated dopaminergic signaling is affected in <z:e sem="disease" ids="C0162635" disease_type="Disease or Syndrome" abbrv="">Angelman syndrome</z:e> </plain></SENT>
</text></document>